Lake Street Capital Initiates Coverage on Beyond Air (NASDAQ:XAIR)

Posted by Francis Steltz on Sep 1st, 2026

Research analysts at Lake Street Capital began coverage on shares of Beyond Air (NASDAQ:XAIR – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Lake Street Capital’s price target would indicate a potential upside of 151.89% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $105.00.

View Our Latest Stock Report on Beyond Air

Beyond Air Trading Down 11.4%

Shares of XAIR stock opened at $3.97 on Tuesday. The firm has a 50-day moving average price of $6.57 and a 200 day moving average price of $10.68. Beyond Air has a twelve month low of $3.85 and a twelve month high of $95.60. The company has a market capitalization of $3.81 million, a price-to-earnings ratio of -0.06 and a beta of 0.23. The company has a current ratio of 3.31, a quick ratio of 3.12 and a debt-to-equity ratio of 7.81.

Beyond Air (NASDAQ:XAIR – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($11.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($10.80) by ($0.20). The firm had revenue of $1.77 million for the quarter, compared to analyst estimates of $1.93 million. Beyond Air had a negative return on equity of 440.26% and a negative net margin of 435.71%.

Insider Buying and Selling

In related news, CEO Robert Scott Goodman purchased 34,722 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the purchase, the chief executive officer directly owned 34,822 shares in the company, valued at approximately $200,574.72. This trade represents a 34,722.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.99% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. purchased a new position in shares of Beyond Air in the 3rd quarter worth about $1,753,000. Osaic Holdings Inc. lifted its position in Beyond Air by 26.4% during the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after buying an additional 34,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Beyond Air by 57.5% during the fourth quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after buying an additional 24,695 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Beyond Air during the third quarter worth approximately $48,000. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Company Profile

(Get Free Report)

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.